Biomx Inc logo

PHGE - Biomx Inc News Story

$6.36 -0.4  -5.6%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £256.2m
Enterprise Value £215.5m
Revenue £n/a
Position in Universe 3937th / 6850

BRIEF-BiomX Announces Dosing Of First Subject In Phase 1A Study Of BX002 Phage Therapy For Inflammatory Bowel Disease

Wed 4th November, 2020 12:04pm
Nov 4 (Reuters) - BiomX Inc  PHGE.A :
    * BIOMX ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE 1A STUDY
OF
BX002 PHAGE THERAPY FOR INFLAMMATORY BOWEL DISEASE
    * BIOMX INC -  RESULTS FROM PHASE 1A STUDY OF BX002 EXPECTED
IN Q1
OF 2021

Source text for Eikon:  ID:nBwcfqcsfa 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.